Findings

What do systematic reviews say?

3,018 questions · 3,100 findings · 369 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 774 · 25%GRADE not reported 108 · 3.5%Very low 727 · 23.5%Low 840 · 27.1%Moderate 474 · 15.3%High 177 · 5.7%

Vitamin C vs allopurinol

Tophus regression · participants with chronic gout and sUA level > 0.36mmol/L

The review found no eligible studies for this question.

1 finding from 1 review

Dietary supplements for chronic gout 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Vitamin C vs allopurinol

Acute gout attacks · participants with chronic gout and sUA level > 0.36mmol/L

The review found no eligible studies for this question.

1 finding from 1 review

Dietary supplements for chronic gout 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Vitamin C vs allopurinol

Withdrawals due to adverse events · participants with chronic gout and sUA level > 0.36mmol/L

1 finding from 1 review

Dietary supplements for chronic gout 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Low

Summary of Findings Table ‐ Ibuprofen 300 mg vs paracetamol

Median (mean) time to use of rescue medication · health problem or population

1 finding from 1 review

Single‐dose intravenous ibuprofen for acute postoperative pain in adults 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 151 participants
Very low

Summary of Findings Table ‐ Ibuprofen 300 mg vs paracetamol

Number of participants reporting an adverse event · health problem or population

It is very uncertain whether summary of Findings Table ‐ Ibuprofen 300 mg changes number of participants reporting or experiencing any adverse event compared with active comparator (acetaminophen) (very low certainty).

1 finding from 1 review

Single‐dose intravenous ibuprofen for acute postoperative pain in adults 2021 · Cochrane Headline outcomes only
RR 1.27 [1.02, 1.59]
1 study · 151 participants
Very low

Summary of Findings Table ‐ Ibuprofen 300 mg vs paracetamol

Number of participants experiencing any serious adverse events · health problem or population

1 finding from 1 review

Single‐dose intravenous ibuprofen for acute postoperative pain in adults 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1 participants
Very low

Summary of Findings Table ‐ Ibuprofen 300 mg vs paracetamol

At least 50% reduction in pain · health problem or population

It is very uncertain whether summary of Findings Table ‐ Ibuprofen 300 mg changes number of participants with at least 50% pain relief at 4 hours compared with active comparator (acetaminophen) (very low certainty).

2 findings from 1 review

Single‐dose intravenous ibuprofen for acute postoperative pain in adults 2021 · Cochrane Headline outcomes only
RR 0.91 [0.58, 1.43]
1 study · 151 participants
Very low
Single‐dose intravenous ibuprofen for acute postoperative pain in adults 2021 · Cochrane Headline outcomes only
RR 1.03 [0.64, 1.66]
1 study · 151 participants
Very low

Summary of Findings Table ‐ Ibuprofen 300 mg vs paracetamol

Number of participants using rescue medication over 4 to 6 hours postinterventions · health problem or population

The review found no eligible studies for this question.

1 finding from 1 review

Single‐dose intravenous ibuprofen for acute postoperative pain in adults 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

All intervention options · people with first recurrence of glioblastoma Interventions: bevacizumab (BEV), BEV + lomustine (LOM), regorafenib (REG), fotemustine…

The review found no eligible studies for this question.

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

BEV+IRI (1 RCT, 79 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

The intervention leads to higher BEV+IRI (1 RCT, 79 participants) (high certainty).

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
RR 2.22 [1.19, 4.18]
1 study · 79 participants
High

Intervention not reported

BEV+VB111 (1 RCT, 128 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

The intervention leads to higher BEV+VB111 (1 RCT, 128 participants) (high certainty).

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
RR 3.77 [2.25, 6.33]
1 study · 111 participants
High

Intervention not reported

BEV+TRC 105 (1 RCT, 49 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

The intervention leads to higher BEV+TRC 105 (1 RCT, 49 participants) (high certainty).

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
RR 6.86 [2.55, 18.41]
1 study · 105 participants
High

Intervention not reported

All intervention options · people with first recurrence of glioblastoma Interventions: bevacizumab (BEV), BEV + lomustine (LOM), regorafenib (REG), BEV + irinotecan…

The review found no eligible studies for this question.

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Outcomes (5 RCTs, 1024 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1024 participants
GRADE not reported

Intervention not reported

BEV(8 RCTs; 498 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 498 participants
GRADE not reported

Intervention not reported

FOM (1 RCT, 32 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

The intervention showed no clear difference in FOM (1 RCT, 32 participants); GRADE not reported.

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
RR 0.44 [0.11, 1.72]
1 study · 32 participants
GRADE not reported

Intervention not reported

BEV+HSPPC96 1 RCTs; 53 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

The intervention showed no clear difference in BEV+HSPPC96 1 RCTs; 53 participants) (low certainty).

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
RR 1.01 [0.33, 3.1]
1 study · 96 participants
Low

Intervention not reported

BEV+ONA(1 RCT; 64 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

The intervention showed no clear difference in BEV+ONA(1 RCT; 64 participants) (low certainty).

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
RR 1.17 [0.57, 2.39]
1 study · 64 participants
Low

Intervention not reported

BEV+CAB (1 RCT; 58 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

The intervention showed no clear difference in BEV+CAB (1 RCT; 58 participants) (low certainty).

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
RR 1.27 [0.61, 2.66]
1 study · 58 participants
Low

Intervention not reported

BEV+DAS (2 RCTs, 83 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

The intervention showed no clear difference in BEV+DAS (2 RCTs, 83 participants) (high certainty).

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
RR 0.52 [0.69, 3.34]
2 studies · 83 participants
High